Proposed Data Collections Submitted for Public Comment and Recommendations

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[INFO-96-22]

Proposed Data Collections Submitted for Public Comment and

Recommendations

In compliance with the requirement of Section 3506(c)(2)(A) of the

Paperwork Reduction Act of 1995 for opportunity for public comment on

proposed data collection projects, the Centers for Disease Control and

Prevention (CDC) will publish periodic summaries of proposed projects.

To request more information on the proposed projects or to obtain a

copy of the data collection plans and instruments, call the CDC Reports

Clearance Officer on (404) 639-7090.

Comments are invited on: (a) Whether the proposed collection of

information is necessary for the proper performance of the functions of

the agency, including whether the information shall have practical

utility; (b) the accuracy of the agency's estimate of the burden of the

proposed collection of information; (c) ways to enhance the quality,

utility, and clarity of the information to be collected; and (d) ways

to minimize the burden of the collection of information on respondents,

including through the use of automated collection techniques for other

forms of information technology. Send comments to Wilma Johnson, CDC

Reports Clearance Officer, 1600 Clifton Road, MS-D24, Atlanta, GA

30333. Written comments should be received within 60 days of this

notice.

Proposed Projects

1. Surveillance and Evaluation of Blood Donors Positive for Human

Immunodeficiency Virus (HIV) Antibody or HIV Antigen (0920-0329). In

1987, the President directed the Department of Health and Human

Services (DHHS) to determine the nationwide incidence of, to predict

the future of, and to determine the extent to which human

immunodeficiency virus (HIV) is present in various segments of our

population. In response, CDC formed an epidemiologic team to summarize

existing information. An extensive review of published and unpublished

data led to the conclusion that even though there is information

suggesting a very large number of Americans were infected, there was no

substitute for carefully and scientifically obtained incidence and

prevalence data. The need to monitor HIV seroprevalence existed on the

national and at the state and local levels for public health

management: targeting and evaluating prevention programs, planning

future health care needs and determining health policy.

On a national basis, HIV seroprevalence projects in 1987 consisted

of monitoring the HIV status of: Civilian applicants for military

service; blood donors, including follow-up risk factor evaluation in

seropositives; and Job Corps entrants. HIV prevalence was studied in

settings of special public health interest including selected colleges

and prisons, among health care workers in hospital emergency rooms and

among Native Americans and homeless persons. Other national data

sources were examined, such as cohort studies of groups at risk,

including homosexual and bisexual men and IV drug users, providing

information on knowledge of AIDS and risk behaviors, changes in

behavior, and incidence of HIV infection.

In 1987, OMB approved the ``Family of HIV Seroprevalence Surveys''

(0920-0232). These surveys included seven seroprevalence surveys which

involved interaction with individuals (non-blinded surveys). One of

these surveys was the surveillance and evaluation of blood donors

positive for Human Immunodeficiency Virus (HIV) Antibody.

In 1993, OMB again approved for 3 years the surveillance and

evaluation of blood donors who test positive for Human Immunodeficiency

Virus (HIV) Antibody and their needle-sharing and sexual partners

(0920-0329). This request is for an additional 3-year approval. The

total cost to respondents is estimated at $3,784.

[[Page 42257]]

------------------------------------------------------------------------

Average

No. of burden/ Total

Respondents No. of responses/ response burden

respondents respondent (in (in

hrs.) hrs.)

------------------------------------------------------------------------

Blood donors (interviews)... 160 1 1.0 160

Blood donors (refuse

interview)................. 120 1 0.1 12

-------------------------------------------

Total................. ........... .......... ........ 172

--------------

------------------------------------------------------------------------

Dated: August 8, 1996.

Wilma G. Johnson,

Acting Associate Director for Policy Planning and Evaluation, Centers

for Disease Control and Prevention (CDC).

[FR Doc. 96-20703 Filed 8-13-96; 8:45 am]

BILLING CODE 4163-18-P